Identifier
Created
Classification
Origin
06TOKYO4853
2006-08-24 05:57:00
UNCLASSIFIED
Embassy Tokyo
Cable title:
AVIAN INFLUENZA: JAPAN WEEKLY REPORT AUGUST 24
how-toVZCZCXRO9392 PP RUEHHM RUEHLN RUEHMA RUEHPB DE RUEHKO #4853 2360557 ZNR UUUUU ZZH P 240557Z AUG 06 FM AMEMBASSY TOKYO TO RUEHC/SECSTATE WASHDC PRIORITY 5710 INFO RUEHZN/ENVIRONMENT SCIENCE AND TECHNOLOGY COLLECTIVE RUEHFK/AMCONSUL FUKUOKA 7791 RUEHNAG/AMCONSUL NAGOYA 7602 RUEHNH/AMCONSUL NAHA 0359 RUEHOK/AMCONSUL OSAKA KOBE 1129 RUEHKSO/AMCONSUL SAPPORO 8902 RUEHRC/USDA FAS WASHDC 8331 RUEAUSA/DEPT OF HHS WASHINGTON DC RUEAIIA/CIA WASHDC
UNCLAS TOKYO 004853
SIPDIS
DEPT FOR AIAG AMBASSADOR LANGE
DEPT FOR OES/IHA SINGER AND FENDRICK
DEPT FOR EAP/J
USDA PASS TO APHIS
HHS PASS TO CDC
HHS FOR OGHA STEIGER, BHAT AND ELVANDER
DEPT PASS TO AID/GH/HIDN DENNIS CARROLL
SIPDIS
E.O. 12958: N/A
TAGS: TBIO KFLU KSTH ECON PREL SOCI JA
SUBJECT: AVIAN INFLUENZA: JAPAN WEEKLY REPORT AUGUST 24
REF: A. 05 STATE 153802
B. TOKYO 4525 AND PREVIOUS
UNCLAS TOKYO 004853
SIPDIS
DEPT FOR AIAG AMBASSADOR LANGE
DEPT FOR OES/IHA SINGER AND FENDRICK
DEPT FOR EAP/J
USDA PASS TO APHIS
HHS PASS TO CDC
HHS FOR OGHA STEIGER, BHAT AND ELVANDER
DEPT PASS TO AID/GH/HIDN DENNIS CARROLL
SIPDIS
E.O. 12958: N/A
TAGS: TBIO KFLU KSTH ECON PREL SOCI JA
SUBJECT: AVIAN INFLUENZA: JAPAN WEEKLY REPORT AUGUST 24
REF: A. 05 STATE 153802
B. TOKYO 4525 AND PREVIOUS
1. There were no significant avian influenza (AI)
developments in Japan during the period August 10 to August
24. No human or animal outbreaks of H5N1 avian influenza
were reported in Japan during the above period.
-- Company to Begin Clinical Test of AI Antiviral --
2. The Toyama Chemical Corporation beginning in FY2006
will conduct clinical trials on T-705, an antiviral agent
that promises to be effective against types A, B and C of
the influenza virus and possibly against avian influenza.
In March 2006, a research team at Utah State University
reported that T-705 showed effectiveness against the H5N1
strain of the virus in animal studies. Toyama plans to
conduct clinical trials simultaneously in Japan and the
U.S. and hopes to have a product ready for the market in
JFY 2009. The company initially plans to produce enough T-
705 for 30 million doses and generate sales of Yen 36
billion (313 million USD). Toyama will license development
and marketing rights to an overseas producer to help offset
the costs and difficulties of mass production on its own.
DONOVAN
SIPDIS
DEPT FOR AIAG AMBASSADOR LANGE
DEPT FOR OES/IHA SINGER AND FENDRICK
DEPT FOR EAP/J
USDA PASS TO APHIS
HHS PASS TO CDC
HHS FOR OGHA STEIGER, BHAT AND ELVANDER
DEPT PASS TO AID/GH/HIDN DENNIS CARROLL
SIPDIS
E.O. 12958: N/A
TAGS: TBIO KFLU KSTH ECON PREL SOCI JA
SUBJECT: AVIAN INFLUENZA: JAPAN WEEKLY REPORT AUGUST 24
REF: A. 05 STATE 153802
B. TOKYO 4525 AND PREVIOUS
1. There were no significant avian influenza (AI)
developments in Japan during the period August 10 to August
24. No human or animal outbreaks of H5N1 avian influenza
were reported in Japan during the above period.
-- Company to Begin Clinical Test of AI Antiviral --
2. The Toyama Chemical Corporation beginning in FY2006
will conduct clinical trials on T-705, an antiviral agent
that promises to be effective against types A, B and C of
the influenza virus and possibly against avian influenza.
In March 2006, a research team at Utah State University
reported that T-705 showed effectiveness against the H5N1
strain of the virus in animal studies. Toyama plans to
conduct clinical trials simultaneously in Japan and the
U.S. and hopes to have a product ready for the market in
JFY 2009. The company initially plans to produce enough T-
705 for 30 million doses and generate sales of Yen 36
billion (313 million USD). Toyama will license development
and marketing rights to an overseas producer to help offset
the costs and difficulties of mass production on its own.
DONOVAN